Subscribe to our Email Alerts
Menu
Home
About Us
Company Overview
Company Values
Board of Directors
Executive Management
Corporate Directory
Products
DAYBUE™ (trofinetide)
Pipeline
Pipeline
Trofinetide
Rett Syndrome
Fragile X Syndrome
NNZ-2591
Phelan-McDermid Syndrome
Angelman Syndrome
Pitt Hopkins Syndrome
Prader-Willi Syndrome
Science
Science Behind Neuren's Products
Scientific Presentations
Publications
Investors
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
News & Media
Media
Contact
Contact Us
Email Alerts
Investors
Home
>
Investors
>
ASX Announcements
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
ASX Announcements
Filter by Year:
2025
2024
2023
2022
2021
2020
2019
2018
Older
Apr 06, 2020
Corporate presentation, 6 April 2020
Apr 02, 2020
First patent in Israel granted for trofinetide
Mar 26, 2020
Change of Director's Interest Notice
Mar 26, 2020
International institution acquires 14% of Neuren
Mar 24, 2020
Change of Director's Interest Notice
Mar 24, 2020
Temporary pause in new enrolments for LAVENDER trial in US
Mar 20, 2020
Trading Halt
Mar 17, 2020
Neuren to capture substantially greater value after Phase 3
Mar 10, 2020
Additional information
Mar 06, 2020
Compelling results for 2591 dose ranging study in PMS model
Previous
1
2
3
4
5
6
Next
